Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
(+/-)Cyclazocine blocks the dopamine response to nicotine
Autore:
Maisonneuve, IM; Glick, SD;
Indirizzi:
Albany Med Coll, Dept Pharmacol & Neurosci, Albany, NY 12208 USA Albany Med Coll Albany NY USA 12208 acol & Neurosci, Albany, NY 12208 USA
Titolo Testata:
NEUROREPORT
fascicolo: 4, volume: 10, anno: 1999,
pagine: 693 - 696
SICI:
0959-4965(19990317)10:4<693:(BTDRT>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
FREELY MOVING RATS; SIGMA-RECEPTORS; RELEASE; MODULATE; CELLS;
Keywords:
(+/-)cyclazocine; (-)cyclazocine; (+)cyclazocine; dopamine; microdialysis; nicotine; nucleus accumbens;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Maisonneuve, IM Albanyany, Coll, Dept Pharmacol & Neurosci, MC-136,47 New Scotland Ave, Alb Albany Med Coll MC-136,47 New Scotland Ave Albany NY USA 12208
Citazione:
I.M. Maisonneuve e S.D. Glick, "(+/-)Cyclazocine blocks the dopamine response to nicotine", NEUROREPORT, 10(4), 1999, pp. 693-696

Abstract

(+/-)CYCLAZOCINE, synthesized by Archer in 1962, was originally tested as a treatment for heroin addiction. (+/-)Cvclazocine is a mu opioid antagonist and kappa opioid agonist, and because of these actions, would be expectedto modulate dopamine release in the nucleus accumbens as well as the reinforcing effects of drugs of abuse. In a recent study (+/-)cyclazocine was reported to decrease cocaine self-administration in rats. The aim of the present study was to determine whether (+/-)cyclazocine would alter the dopaminergic effects of nicotine that are thought to mediate its rewarding effects. Using in vivo microdialysis in awake and freely moving rats, we investigated the effect of (+/-)cyclazocine (0.5 mg/kg, i.p.) on the acute dopamine response to nicotine (0.32 mg/kg, i.v. over a 5 min period, infused 30 min later) in the nucleus accumbens. (+/-)Cyclazocine significantly attenuated the increase in extracellular dopamine levels induced by the nicotine infusion and enhanced nicotine-induced increases in dopamine metabolites. (+/-)Cyclazocine alone did not significantly affect extracellular dopamine levels. However, both the (+) and (-) enantiomers of cyclazocine did alter basal dopamine levels and these effects made it difficult to assess their individual interactions with nicotine. The results suggest that the effects of both enantiomers contribute to the effects of the racemate; (+/-)cyclazocine may decrease the rewarding effect of nicotine and may be the prototype of a potentially novel treatment for smoking. NeuroReport 10:693-696 (C) 1999 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 12:53:59